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INTRODUCTION 
 
        Corticosteroids (CS) are the most important class of anti-
inflammatory drugs, used frequently. The therapeutic outcome of 
corticosteroids have been known and are employed for more than 65 
years. Though the major advancement in discovering the hidden 
molecular mechanisms has been made in the last 20-25 years. The use of 
corticosteroids for their highly potent action was at its peak during the 
1960s and 1970s and ineluctably they were used inappropriately and 
uncritically, when the untoward effects became apparent and a stage to 
think about their lavish use in all forms arrived.  
 Adverse effects ranging from acne to intestinal perforation and 
adrenal crisis has been documented. Both short term or long-term 
corticosteroids use has their own side-effects involving major systems of 
the body. Potency, dose, duration, frequency and form of the drug used in 
various routes also contributes to the manifestation of adverse effects.  
 Corticosteroids treatment brought adverse events of such a 
proportion that the upcoming major group of anti-inflammatory drugs, 
were named as nonsteroidal anti-inflammatory drugs (NSAIDs). 
Corticosteroids were voted by the American Contact Dermatitis Society 
as “Allergen of the year” in 2005
1
. 
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 Even today, they are the established therapy for reducing 
inflammation and immune activation in numerous disease conditions like 
asthma, rheumatoid, vascular, allergic, collagen, inflammatory bowel, 
dermatological, ocular and other systemic diseases and also in allo-
transplantation. Their utilization has leaping up continuously in recent 
years as their therapeutic effects are indispensable and had made marvels 
in managing certain disease conditions in spite of their adverse effects. 
For appropriate use of corticosteroids, a basic knowledge of 
pharmacology, clinical usage guidelines and adverse effects are essential. 
       In this study, the prevalence of various ocular manifestation in 
patients on long term corticosteroids in multiple routes of administration 
had been analysed. 
 
  
 
 
 
 
3 
 
REVIEW OF LITERATURE 
Corticosteroids are a group of 21 -carbon steroid hormones 
produced by adrenal cortex of vertebrates, and the synthetic analogues of 
these hormones were synthesized. 
Corticosteroids were first made accessible for general use in 1950. 
Edward Calvin Kendall, Tadeus Reichstein and Philip Showalter Hench 
were awarded The Noble Prize in Physiology or Medicine in 1950 “for 
their discoveries relating to the hormones of the adrenal cortex, their 
structure and biological effects.” 
CLASSES AND THEIR FUNCTIONS : 
    Two main division of corticosteroids are glucocorticoids (GC) and 
mineralocorticoids. Natural steroid hormones are cortisol or 
hydrocortisone, corticosterone, cortisone and aldosterone. Zona fasiculata 
and zona reticularis of adrenal cortex produce cortisol, a glucocorticoid. 
Zona glomerulosa of adrenal cortex
 
produce the mineralocorticoids 
aldosterone and corticosterone
2
. 
The principal function of glucocorticoids is to balance 
carbohydrates, fat and protein metabolism by stimulating 
gluconeogenesis, inhibition of glucose uptake in muscle and adipose 
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tissue, mobilization of aminoacids from extra-hepatic tissues, and 
stimulation of fat breakdown in adipose tissue. They also got cardinal role 
as anti-inflammatory agent mediated by transrepression
3
 which is by 
blocking the reaction of the inflammatory mediators, and by 
transactivation which is by generating anti-inflammatory mediators. The 
immunosupressive action of GC are mediated by suppressing delayed 
hypersensitivity reactions by direct effect on T-lymphocytes. The anti-
proliferative action of GC are mediated by DNA synthesis inhibition and 
turnover of epidermal cell. The vaso-constrictive effect of GC is by 
inhibiting the response of vaso-constrictive mediators like histidine
3
. 
Mineralocorticoids main role is to regulate electrolyte and water 
balance by regulating ion transport in epithelial cells of the renal tubules 
of the kidney
3
. It does so by active re-absorption of sodium and an 
associated passive re-absorption of water with active secretion of 
potassium in the principal cells of the renal tubules. This results in an 
increase of blood pressure and blood volume
2
. 
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BIOSYNTHESIS OF CORTICOSTEROIDS: 
      Corticosteroids are naturally produced within the adrenal cortex 
from cholesterol in the body, catalysed by enzymes of cytochrome p450 
family, which are located in the mitochondrial inner membrane and needs 
adrenodoxin as co-factor except for 21-hydroxylase and 17-alpha 
hydroxylase. In lysosomes cholesterol esters are converted to free 
cholesterol
2
. 
 First synthetic steroid was produced using a 36-step process that 
started with deoxycholic acid from ox bile by Lewis & Co at a higher 
cost
4
. Russell Marker produced much cheaper steroid from diosgenin by a 
four steps process from wild Mexican yams. This resulted in much 
reduction in price
5. 
Hence corticosteroids were considered as a wonder 
cure in 1950s and prescribed liberally.  
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BIOSYNTHESIS OF CORTICOSTERIDS 
 
Figure 1: Pathway of corticosteroid bio-synthesis. Orange color box shows the 
pathway in Zona glomerulosa and gray color box shows pathway in zona fasciculata 
and zona reticularis. CYP11A1, cholesterol side-chain cleavage enzyme; 3beta-HSD, 
3beta-hydrosysteroid dehydrogenase; CYP17, steroid 17alpha-hydroxylase; 
CYP11B2, aldosterone synthase; CYP11B1, steroid 11beta-hydroxylase
2
. 
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MECHANISM OF ACTION OF STEROIDS: 
Corticosteroids in any form will cross the cell membrane and forms 
a steroid-receptor complex by reacting with cytoplasmic receptor 
proteins. This complex proceed into the nucleus and binds to DNA, 
which changes the transcription of mRNA. This binding process results in 
production of glycoprotein, especially lipocortin, which inhibits the 
enzyme phospholipase A2 activity that cascade the reactions for 
inflammatory mediators production ie., by inhibiting arachidonic acid 
metabolite like prostaglandins, leukotrienes and their oxygen free 
radicals
6,7
.  
Corticosteroids also produce lipoprotein that inhibits the synthesize 
of proinflammatory cytokines like interleukin-1, interleukin-2, IL-2 
receptors, interferon-gamma, tumor necrosing factor-alpha and various 
colony stimulating factors. This will manifests the anti-inflammatory, 
immunosupressive and anti-myogenic action of the corticosteroids. 
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Figure 2: MECHANISM OF ACTION OF 
CORTICOSTEROIDS 
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Figure 3:  
 
 
USES OF CORTICOSTEROIDS: 
Synthetic corticosteroids have a extensive scope of uses in a wide 
range of disease conditions from skin diseases to brain tumors due to their 
anti-inflammatory, anti-allergic action and immunomodulator action. 
Replacement Therapy : In acute adrenal insufficiency, hydrocortisone 
bolus of 100 mg is given intravenously. In chronic adrenal insufficiency 
where patients present with adrenal crisis, need daily therapy of 
corticosteroids (Coursin & Wood, 2002)
9
. 
In all classical congenital adrenal hyperplasia patient replacement therapy 
with hydrocortisone is required. 
10 
 
Rheumatic disorders : Inflammatory rheumatic diseases like systemic 
lupus erythematosus and vasculitis like Wegener’s granulomatosis, 
polyarthritis nodosa, giant cell arthritis, Churg-Strauss sundrome. Initially 
with high oral dose of prednisone (1 mg/kg), then taper to minimal 
effective dose. 
Renal diseases : In nephrotic syndrome, prednisolone of 1-2 mg/kg given 
for 6 weeks, then tapered over 6-8 weeks
8
. 
Allergic disease : acute allergic conditions like urticaria, hay fever, bee 
sting, serum sickness, contact dermatitis and angioneurotic edema can be 
treated with glucocorticoids in adequate dose as supplements to the 
primary therapy. 
Bronchial asthma and other pulmonary conditions : Steroids 
commonly used for bronchial asthma in inhalational or oral form. In 
chronic obstructive lung diseases and interstitial lung diseases, 
corticosteroids were employed if there is some evidence of reversible 
obstructive disease. 
Ocular diseases : In a large number of ocular inflammatory conditions, 
corticosteroids are used in topical, local or systemic form. 0.1% 
dexamethasone sodium phosphate, 1% prednisolone acetate drops were 
11 
 
potent steroids in use. Low potent topical steroids used are 
fluromethalone, loteprednol etabonate. 
Skin diseases : 1% hydrocortisone ointment is used for eczematous 
eruptions. Systemic steroids are used for lepra reaction, pemphigus 
vulgaris, and in many connective tissue disorders. 
Gastrointestinal diseases : Inflammatory bowel disease can be treated 
with corticosteroids in selected patients with hydrocortisone, 
prednisolone, and budesonide. 
Hepatic diseases : Glucocorticoids are used in autoimmune hepatitis. 
Malignancies : Antilymphocytic effects of glucocorticoids  is used in the 
chemotherapy of acute lymphocytic leukemia and lymphomas. 
Cerebral edema : In cerebral edema associated with trauma or 
cerebrovascular accidents, neoplasms and parasites, corticosteroids are 
used to reduce the inflammation. 
Miscellaneous diseases and conditions : Sarcoidosis with lung 
involvement, prednisone is employed. 
  Organ transplantation : High-dose of prednisone is given at the time 
of transplant surgery along with immunosuppressive therapy and 
maintenance regimen is continued. 
12 
 
  Spinal cord injury : Spinal cord injuries treated with intravenous large 
dose of methylprednisolone within 8 hours showed significant decrease 
in neurological defects. 
ROUTE OF ADMINISTRATION : 
 Corticosteroids are used in many routes for the desired therapeutic 
effect like topical, inhalational, oral, intra-venous, intra-muscular, intra-
articular, intra-vitreal, sub-conjunctival, sub-tenon and intra-lesional. 
 Topical steroids are utilized as eye drops/ointments, ear drops, 
nasal drops, local creams, lotions and ointments. They are mainly used in 
eye conditions like uveitis, keratoconjunctivitis and post-ope 
inflammation and in dermatological conditions like pemphigus and 
contact dermatitis. Topical steroids exhibits their anti-inflammatory, 
immunosupressive, anti-proliferative action on keratinocytes and 
suppress collagen synthesis by fibroblast and prevent hypertrophic scar or 
keloid formation. Topical steroids are classified as four classes based on 
their potency, antigenic behavior and cross reactivity as demonstrated by 
patch test. Similarly, S.Coopman in 1989
10,11 
grouped them in four classes 
based on their chemical structure. Allergic reactions to any one member 
of a class typically indicates an intolerance of all members of the class. 
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Group A : Hydrocortisone type 
 Hydrocortisone, methylprednisolone, prednisolone, prednisone and 
triamcinolone (short to medium acting GC). 
Group B : Acetonides ( and related substances) 
 Amcinonide, budesonide, desonide, flucinolone acetonide, 
fluocinonide, halcinonide and triamcinolone acetonide. 
Group C : Betamethasone type 
 Beclometasone, betamethasone, dexamethasone, flucortolone, 
halometasone and mometasone. 
Group D : Esters. 
Group D1- Halogenated (less labile) 
 Alclometasone dipropionate, betamethasone dipropionate, 
betamethasone valerate, clobetasol propionate, clobetasone butryate, 
fluprednidene acetate and mometasone furoate. 
Group D2- Labile prodrug esters. 
 Ciclesonide, cortisone acetate, hydrocortisone aceponate, 
hydrocortisone acetate, hydrocortisone butepranete, hydrocortisone 
butyrate, hydrocortisone valerate, prednicarbate and tixocortol pivalate. 
14 
 
Inhalational steroids are used as inhaler or nebulizer form mainly in 
chest medicine department. Example: fluticasone furoate, fluticasone 
propionate, triamcinolone acetonide, beclomethasone dipropionate, 
mometasone, flunisolide and budesonide
12,13
. 
Oral steroids are used in almost all chronic conditions like 
rheumatoid arthritis, lupus nephritis, lepra reaction,etc,. in all specialities. 
Examples : Prednisone, prednisolone and dexamethasone. 
Systemic steroids in all other forms are used for acute conditions 
like angioedema, acute allergy, anaphylaxis, adrenal insufficiency crisis, 
atopic dermatitis and so on
14
. Example: Methlyprednisolone, 
dexamethasone and cortisol. Intra-venous steroids are widely used in 
treating post-traumatic head injuries. 
Other routes like intra-vitreal where triamcinolone acetonide is used 
in ocular pathologies like diabetic macular edema, retinal vein occlusion, 
cystoid macular edema, age-related macular degeneration and uveitis, 
posterior sub-tenon injection, depot or repository or sub-conjunctival 
injection used in ocular inflammatory conditions
15
. Intra-articular steroids 
are used in rheumatoid arthritis and intra-lesional steroids are used in 
carpal-tunnel syndrome, keloid and gout. 
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ADVERSE EFFECTS OF STEROIDS : 
Corticosteroids have diverse adverse effects ranging from very 
subtle to very severe forms involving all parts of the body
16
. 
1.  Central nervous system : steroid psychosis, depression, anxiety, 
euphoria, insomnia and pseudotumor cerebri. 
2.  Cardiovascular : Fluid retention and hypertension. 
3.  Metabolic : moon-face, buffalo hump, truncal obesity, muscle 
wasting (anti-anabolic effect), hypocalcemia, hypokalemia, 
hyperlipidemia 
4.  Endocrine : weight gain, glycosuria, hyperglycemia, diabetes, 
impaired growth. 
5.  Bone and muscle : osteoporosis, proximal myopathy and wasting, 
aseptic necrosis of hip, pathological fracture. 
6. Gastrointestinal : gastritis, peptic ulcer, colitis, pancreatitis and 
intestinal perforation. 
7.  Eyes: cataract and glaucoma, central serous chorio-retinopathy 
rarely. 
8.  Skin : easy bruising and thinning. 
16 
 
9.  Increased susceptibility to infections, reactivation of TB. 
10.  Physiological : adrenal and/or pituitary suppression, withdrawal 
syndrome, and adrenal crisis. 
Pregnancy has low but significant teratogenicity effect like few 
birth defects in pregnant women treated with steroids. Hence 
corticosteroids are contra-indicated in pregnancy. 
RISK FACTORS FOR SIDE EFFECTS: 
      Possible side-effects in topical steroids depends on steroid type and 
vehicle like cream, ointment, lotion or gel, application method like 
frequency and duration, nature and extent of skin disease and patient 
factors like age and site of lesion. 
Side effects of systemic steroids use is based on the drug potency, 
dose, frequency and duration of use of the drug. 
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OCULAR MANIFESTATIONS OF LONG-TERM 
USE OF STEROIDS : 
Corticosteroids are widely used in numerous disease conditions. 
Following corticosteroids utility in any form for a long duration 
regardless of their indications, adverse effects on the eyes have been 
demonstrated and documented. Very common adverse effects are like the 
development of cataract, elevated intra-ocular pressure (IOP) and 
glaucoma, and also vary rare complications like retinal emboli and central 
serous choroido-retinopathy has been documented so far
17
. 
Corticosteroids are most precious topical drug following 
keratoplasty, cataract surgery and trabeculectomy. They are also used in 
keratitis and allergic conjunctivitis. 
Common ocular manifestations of topical corticosteroids 
encountered includes, 
Ø Keratitis: viral, bacterial, fungal. 
Ø Glaucoma. 
Ø Others: mydriasis, blurred vision, refractive changes, ptosis, lens 
opacities. 
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Ocular manifestations of systemic corticosteroids are, 
Ø Cataract, 
Ø Papilledema in children. 
CATARACT : 
The posterior subcapsular cataract type (PSCC) is the type of 
cataract that typically complicate in long-term systemic corticosteroid 
therapy, although nuclear lesions may be seen very rarely
18,19
. Cataracts 
association with steroid therapy was first recognized in patients treated 
for rheumatoid arthritis and later, in bronchial asthma
20,21,22
. 
Black et al., 1960 proposed a well association between PSCC and 
systemic steroids
21
. 
Garbe et al., 1998 proposed that an inhaled or intranasal 
corticosteroids of high dose ( > 1 mg/day ) and low to medium ( <1 
mg/day ) average daily doses, after prolonged period (> 2 years ), the 
likelihood of incidence of cataract extractions in elderly people with 
relative risk, 3.06 and 1.63 respectively
26,27
. 
Cumming et al., 1997 did a cross-sectional study and reported 
the association of inhaled corticosteroid with an increased risk of cataract 
formation
28
. 
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Bonomi L., 1989 reported association of cataract formation 
induced by topical ocular corticosteroids and miotics
29
. 
The use of high-dose intra-ocular steroids to treat retinal 
neovascularization and inflammation also results in the developement of 
PSCC. 
The prevalence of cataract was found to be influenced by the daily 
dose and the cumulative dose of the drug and duration of the treatment, 
age of the patient and ethnic origin based on previous studies
20-24
. 
Children and Hispanic people may be more susceptible. The lesions may 
resolve partially or completely after withdrawal of the drug or may 
progress despite withdrawal
30
. 
Mechanisms involved in the corticosteroid induced cataract 
formation includes elevation in glucose levels, caused by an increased 
gluconeogenesis rate leading to Na+ /K+ -ATPase inhibition, increased 
permeability to cations and glucose-6-phosphate-dehydrogenase and 
RNA synthesis inhibition, finally loss of ATP; and covalent binding of 
steroids to lens proteins
31
. 
     Glucocorticoids establish a stable covalent bonding with the lysine 
residues of lens proteins in a non-enzymatic way
32
. These bonds are seen 
only in steroid-induced cataracts, but not in other human cataracts or 
20 
 
normal human lenses. Hence, DNA-independent nongenomic 
mechanisms mainly seem to be associated in developing these 
glucocorticoid receptor mediated effects in lens opacification and cataract 
formation. 
Histologically, PSCC is associated with posterior migration of the 
lens epithelial cells from the lens equator to the visual axis on the inner 
surface of the posterior capsule. During their migration to or after their 
arrival at the posterior axis; the cells undergo aberrant enlargement. 
These swollen cells are termed as Wedl (or bladder) cells
33
. 
Clinically or histologically, PSCC formation occurring follwing 
corticosteroid use cannot be distinguished from senescent PSCC 
formation
34. 
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Figure 4: Posterior sub-capsular cataract in diffuse and retro-illumination 
in slit-lamp. 
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GLAUCOMA : 
A rise in intraocular pressure (IOP) is the second most common 
adverse effect of corticosteroid therapy. If the elevation in IOP effect is of 
ample magnitude, for an adequate duration, optic nerve damage and 
corresponding visual field defect (steroid-induced glaucoma) may occur.  
McLean in 1950 reported an increase in IOP induced by systemic 
administration of adrenocorticotropic hormone (ACTH)
35
. 
 Francois in 1954 documented the first case of elevated IOP 
induced by local administration of steroid (cortisone)
36
. 
 It has long been known fact that IOP alter diurnally and it has been 
suggested that this may be associated to cortisol levels. The diurnal IOP 
culminate at around 0700 hours and the trough occurs during the early 
evening, since the daily fluctuation in IOP closely correlates with the 
plasma cortisol levels
37
. Secondary rise in IOP in adrenal gland 
hyperplasia cases had been reported
38,39
. 
Corticosteroid can give rise to a clinical picture closely resembling 
that of primary open angle galucoma (POAG), with elevated IOP, 
decrease in outflow facility, open angles, and eventually optic nerve 
cupping and visual field loss. 
23 
 
 Steroid-induced elevation of IOP has been observed to occur with 
various routes of steroid administration, but is most often identified as an 
adverse effect of topical corticosteroid used as drops or ointment with 
drug like dexamethasone or prednisolone
40,41,77 
and also with chronic 
inhaled or nasal steroids
42
, subconjunctival, sub-Tenon’s injection
423
and 
systemic steroid therapy
44
. No gender or racial predilection exists. 
 Classic studies of Armaly and Becker indicates that 5-6% of normal 
individuals develop marked IOP rise after 4-6 weeks of topical 
dexamethasone or betamethasone administration
45,46
.This outcome 
increases in greater frequency, on higher dose, or for a longer period
47
. 
Weinreb et al reported acute rise of IOP within hours of initiating 
intensive topical steroid therapy
48
. 
In responsive patients, the IOP typically rises after several weeks of 
continual corticosteroid therapy and returns to normal following cessation 
of such therapy. Steroid induced elevated IOP or glaucoma also 
documented when steroids used as lotions and creams by penetrating the 
eyelid skin.  
Systemic steroids also produce steroid induced glaucoma based upon 
the dose, frequency and duration. Periocular steroids injections in the 
form of repositories
47
 or depot preparations are also capable of elevating 
the IOP. 
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Recently, intra-vitreal injection of triamcinolone acetonide for 
diabetic macular edema or retinal vein occlusion has become popular. 
30% of eyes having this treatment will show a transient rise in IOP. In 
some patients , the IOP may persist and may require topical medications, 
laser trabeculoplasty or even trabeculectomy to lower the IOP and 
prevent optic nerve damage. 
Jonas JB et al.2005 did a meta-analysis study of 272 patients (305 
eyes) receiving an intravitreal injection of 20 mg triamcinolone acetonide 
as treatment for diffuse diabetic macular edema, exudative age-related 
macular degeneration, retinal vein occlusions, uveitis, pseudophakic 
cystoid macular edema and other reasons
88
. With mean follow-up of 
10.4+/-6.7 months, intraocular pressure higher than 21 mm Hg, 30 mm 
Hg, 35 mm Hg, 40 mm Hg were observed in 41.2%,11.4%, 5.5%, 1.8% 
patients respectively. All were treated with anti-glaucoma medications 
but in 3 eyes filtering surgery was done. Younger age was significantly 
associated with triamcinolone-induced ocular hypertension. No 
association was found between triamcinolone-induced ocular 
hypertension and gender, refractive error, diabetes mellitus and reason for 
treatment. 
Vasconcelos et al.2008 did a retrospective study of 150 patients 
receiving 4 mg of intravitreal triamcinolone acetonide for diabetic 
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macular edema, neovascular age-related macular degeneration, choroidal 
neovasularization due to other etiology, central retinal vein occlusions 
and branch retinal vein occlusion. Secondary ocular hypertension (SOH) 
defined as intraocular pressure of >/=21 mm Hg was recorded in 32.0% 
eyes during a mean follow-up of 7.7 months. No association was found 
between SOH and age, sex, systemic hypertension, diabetes mellitus, 
indication for IVTA injection, prior cataract surgery, or concurrent 
photodynamic therapy. Peak IOP was lower in vitrectomized eyes. Risk 
factors for SOH are patients with prior galucoma and higher baseline 
IOP
89
. 
Mechanism of the corticosteroid induced glaucoma: 
   Corticosteroids causes rise in IOP by decreasing aqueous outflow 
facility
49-52
. Steroid specific receptors on the trabecular meshwork cells 
may be involved in the occurrence of steroid-induced glaucoma
53
. In 
recent studies the possible role of genetic influences in the 
pathophysiology has been elucidated. 
The principal mechanism of action of steroids that is accountable 
for elevation of IOP is by their membrane stabilizing action
54
. 
Hyaluronidase sensitive glysosaminoglycans (mucopolysaccharides) are 
usually present in the aqueous outflow system. These 
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glycosaminoglycans in the polymerized state may get hydrated producing 
a ‘biological edema’. Hence, these are persistently break down by the 
hyaluronidase within the lysosomes of the goniocytes. 
Francois and Armaly both proposed that corticosteroids stabilize 
the lysosomal membrane of the goniocytes,that could decrease the release 
of lysosomal hyaluronidase, thus ends with relative inhibition of 
hyaluronate depolymerisation. The following collection of polymerised 
glycosaminoglycans in the trabecular meshwork, results in an increased 
outflow resistance
55,56,61,78
. Glucocorticoid use increases expression of 
collagen
57
, fibronectin
58
 and elastin
59
 in the extracellular matrix within the 
trabecular meshwork and encourage expression of sialoglycoprotein
60
. 
   Two designs of extracellular deposition have been described in the 
TM of steroid-induced glaucoma patients; collection of fine fibrillar 
material in the juxtacanalicular region and fingerprint-like deposition of 
the material in the uveal meshwork. 
A decrease in the production of prostaglandins by corticosteroids, 
that regulates aqueous facility has also been put forward as one of the 
mechanisms leading to elevation of IOP
62
. 
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Fig 05- FUNDUS IMAGE SHOWING LEFT OPTIC DISC WITH 
C:D-0.6 IN COLOR & RED FREE MODE. 
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Fig 06- FUNDUS IMAGE SHOWING RIGHT OPTIC DISC WITH 
C:D-O.7 IN COLOR & RED FREE MODE 
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Figure 07- Humphrey Field Analysis of right eye showing 
arcuate scotoma 
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GENETICS: 
Several authors have put forwarded a genetic susceptibility for 
corticosteroids
50,52,64
. Becker and Hahn in 1964, proposed that patient 
response to corticosteroids could be explained by a monogenic autosomal 
mechanism. Armaly and Becker refined this, and proposed that medium 
responders were heterozygotes while high responders were homozygotes. 
 Several genes have been demonstrated to be up-regulated in 
dexamethasone-treated TM cells, of which myocilin gene (TM-inducible 
glucocorticoid response or TIGR, gene product)
65-68
, which is a 55 kDa 
protein is extensively studied. The role of myocilin in steroid-induced 
elevated IOP and glaucoma has been proposed because: 1. it is extremely 
expressed in trabecular cells exposed to glucocorticoids, 2. the delay in its 
expression is similar to the delay in the pressure rise in glucocorticoids 
treated eyes and 3. the dose required to cause the protein expression is 
similar to that needed to raise the IOP
69
.   
Risk factors for rise in IOP in patients on steroid therapy have been 
identified, although its mechanism is partly understood.  
1.  Patients with primary open-angle glaucoma
50,63
 
2.  Their first-degree relatives with POAG
70,71
. 
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3.  High myopia
72
. 
4.  Diabetes mellitus
73
. 
5. A history of connective tissue disorders, especially rheumatoid 
arthritis
74
. 
6.  Pigment dispersion syndrome
75
. 
7.  Eyes with traumatic recession of the anterior chamber angle and their 
fellow eyes
76
. 
8.  Endogenous hypercortisolism
39
. 
9.  The relative potency, concentration, frequency, and duration of use of 
the steroids.  
10. Combined us of topical and systemic steroids has an additive effect 
on IOP. 
No sex or racial predilection exists for steroid-induced glaucoma. 
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CENTRAL SEROUS CHORIORETINOPATHY : 
CSCR is an idiopathic ocular condition which is distinguished by 
pathologic accumulation of serous fluid at the posterior pole of the 
fundus, producing a localized retinal detachment
82
. Patients usually 
present with diminished vision, central scotoma, metamorphopsia and/or 
chromatopsia when the macular retina is associated, but are mostly 
asymptomatic with extrafoveal or eccentric lesions.  
Although, the pathogenesis of the disease is partly understood, it 
has been accredited to dysfunction in the retinal pigment epithelium 
(RPE)
83
, the choroid
84
, or both. CSCR is generally seen in young or 
middle-aged adults, with some male predominance. 
Glucocorticoids have been strongly incriminated as a pathogenic 
factor
85
, since CSCR occurs both in conditions of endogenous 
glucocorticoids administered exogenously
86
. 
CSCR may manifest when exogenous corticosteroids are used by 
any route like systemic, inhalational, local , dermatologic
87
 and topical. 
Even some forgotten exogenous corticosteroids use also had caused 
central serous chorioretinopathy. 
      Lowdew et al 1981, Wakakura et al 1987, Tittl et al 1999 have 
documented the prevalence of CSCR with exogenous corticosteroids use 
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as 10 percent
90,91,92
. Few more recent studies reported the prevalence as 
29% and 52%, since CSCR can develop from few days to several years 
after the start of exogenous steroids and also even in low dose as 10-15 
mg per day orally93,97. The incidence increases with the older people as 
they are more vulnerable even at small doses of steroids
94
. 
   Accordingly, some authors have argued that CSCR should be added to 
the list of ocular complications of steroids, given by any route
95,96,97
. 
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Figure 8: Fundus image of left eye showing central 
serous chorioretinopathy in color and red free mode 
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Figure 9: Optical coherence topography showing 
CSCR in left eye. 
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Figure10 : Fundus flurosceine angiography of right eye 
showing ‘ink blot’ appearance in CSCR 
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AIM AND OBJECTIVES 
AIM : 
To analyse the ocular effects of long term use of corticosteroids by 
various routes of administration for various disorders treated in a tertiary 
care hospital. 
OBJECTIVES : 
1.  To study the prevalence of the ocular effects of long term use of 
corticosteroids in various diseases. 
2.  To emphasis the importance of regular ocular examination for the 
patients on long term steroid therapy. 
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MATERIAL AND METHODS  
230 patients on long-term use of corticosteroids for various 
disorders attending eye op within our inclusion criteria were evaluated for 
any ocular manifestations in the department of Ophthalmology in 
Coimbatore medical college hospital for a period of one year from Jan-
2017 to Dec-2017. 
    Detailed history including the past medical history and treatment 
history, form, frequency and duration of usage of corticosteroids was 
recorded. Blood pressure and blood sugar was recorded. 
 A comprehensive ophthalmological examination was done including 
visual acuity, intra-ocular pressure measurement, color vision, visual 
fields, slit lamp biomicroscopy and ophthalmoscopic examination. 
Study design : 
This is a cross-sectional study involving patients on long term use of 
corticosteroids for various systemic diseases.                                                                           
Setting : 
Study was conducted at the Department of Ophthalmology, 
Coimbatore Medical College Hospital, Coimbatore. 
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Duration of the study : 
One year period – from January 2017 to December 2017. 
Study population : 
Patients attending the Dermatology, Thoracic medicine, 
Rheumatology and Ophthalmology OPD in Coimbatore medical college 
hospital were included in the study based on selection criteria. 
Inclusion criteria : 
1. Patients on long term use ( > 6 months ) of corticosteroids 
for any disease. 
2. Age group:15-50 years. 
3. Patients on various routes of corticosteroids administration 
(topical, inhalation and systemic). 
Exclusion criteria :  
1. Patients with history of any previous primary ocular diseases. 
2. Patients with diabetes, hypertension. 
3. Patients with history of ocular trauma. 
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STUDY METHODOLOGY : 
The study population of 230 patients between 15-50 years of age 
on long-term use of steroids in all forms were taken up for study for 
ocular manifestations of corticosteroids. 
Informed consent was obtained from the patients selected for study. 
Data were collected using structured questionnaire which 
comprises socio-demographic characteristics like age, gender, detailed 
medical history, form and duration of usage of corticosteroids. 
Clinical Examination includes : 
1. Uncorrected and best corrected Visual Acuity for distant vision 
using Snellen’s distance vision chart and Snellen’s near vision chart 
for near vision. 
2. Intra-ocular pressure measurement using Goldmann applanation 
tonometry. 
3. Anterior segment examination including slit lamp bio-microscopy 
with undilated and dilated pupil. 
4. Fundus examination using slit lamp bio-microscopy with +90D lens 
and indirect ophthalmoscope. 
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5. Color vision using Ishihara chart. 
6. Visual fields using Humphrey field analyzer. 
Data were analysed for the prevalence of ocular effects.  
On slit lamp bio-microscopy, anterior segment is inspected and 
lens changes are documented based on Lens Opacities Classification 
system III (LOCS III). It is a standardized photographic comparison 
system for grading the features of the human age-related cataract
98
. It 
consists of six slit-lamp images for grading nuclear color (NC) and 
nuclear opalescence (NO), five retro-illumination images for grading 
cortical cataract (C), and five retro-illumination images for grading 
posterior subcapsular (P) cataract. Cataract severity is graded on a 
decimal scale, and the standards have regularly spaced intervals on a 
decimal scale. 
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Figure 11 :  Lens Opacities Classification system III (LOCS III) 
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STATISTICAL ANALYSIS 
 
    Data analysis was performed using statistical software package 
SPSS version 22.9. Both descriptive and inferential statistics were used. 
The data of categorical and ordinal variable were represented as 
frequencies and proportions. The data of continuous variable was 
represented as mean +/- standard deviation or mean based inter quartile 
range depending on the distribution of data. The comparison of 
continuous variable across different subgroups was done using one way 
analysis of variance (ANOVA). The comparison of categorical and 
ordinal variable across different subgroups were done using chi-square 
test. Correlation analysis was done by estimating Pearson estimation 
coefficient. P value of less than 0.05 was considered significant.
44 
 
RESULTS AND OBSERVATION 
DEMOGRAPHIC CHARACTERISTICS OF PARTICIPANTS 
Demographic and clinical data of 230 patients are presented below 
AGE DISTRIBUTION 
Age of the patients ranged from 15 years to 50 years. The mean age of the 
study population is 39.36 years, the standard deviation being 8.046. 
 
TABLE 01: Age distribution of study participants 
 
AGE GROUP FREQUENCY(n) PERCENTAGE(%) 
0-20 1 0.43 
21-30 39 16.96 
31-40 80 34.78 
41-50 110 47.83 
Total 230 100.00 
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CHART 01-Age distribution 
 
 
 
Majority of the patients belonged to the age group of 41-50 (n=110, 
47.83%). 
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GENDER DISTRIBUTION 
 
Female were more in the study group (n=129, 56.1%). 
 
 
TABLE 02- Gender distribution 
SEX FREQUENCY (n) PERCENTAGE (%) 
Female 129 56 
Male 101 44 
Total 230 100.0 
 
CHART 02- Gender distribution 
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TABLE No 03- Frequency of steroids used 
 
DRUGS FREQUENCY PERCENTAGE 
Prednisolone 134 58.3 
Betamethasone 17 7.4 
Cortisone 1 .4 
Prednisone 7 3.0 
Prednisolone, Budesonide 25 10.9 
Budesonide 21 9.1 
Dexamethasone 17 7.4 
Fluticasone 6 2.6 
Prednisolone acetate 2 .9 
Total 230 100.0 
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CHART O3- Distribution of steroids used 
 
 
 
      Prednisolone was the oral steroids which was used by most of the 
patients in our study group (n=134, 58.3%), followed by prednisolone 
with budesonide (n=25, 10.9%). Cortisone was least the used (n=1,0.4%). 
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ROUTES OF USE OF STEROIDS 
 
TABLE 04- Various routes of use of steroids 
 
ROUTE OF 
ADMINISTRATION 
FREQUENCY (n) PERCENTAGE (%) 
External 14 6.1 
Inhalational 28 12.2 
Oral 137 59.6 
Oral & Inhalational 32 13.9 
Topical 14 6.1 
Topical & Sub-tenon 5 2.2 
Total 230 100.0 
50 
 
CHART 04- Routes of steroids used 
 
 
 
 Majority of patients had steroids in oral route (n=137, 59.6%), followed 
by oral and inhalational steroids (n=32, 13.9%). Topical with sub-tenon 
steroids were least used (n=5,2.2%)…………………………………….. 
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TABLE 05-Dose distribution of oral steroids 
 
DOSAGE 
(mg) 
FREQUENCY (n) 
PERCENTAGE 
(%) 
1 to 5 55 40.1 
6 to 10 49 35.8 
11 to 15 22 16.1 
16 to 20 8 5.8 
21 to 25 3 2.2 
Total 137 100.0 
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 Chart 05- Dose distribution of oral steroids 
 
     
    
 
Most of the patients had 1 to 5 mg of oral steroids (n=55, 40.1%), 
followed by 6 to 10 mg (n=49, 35.8%). 21 to 25 mg was least used 
(n=3, .2%). 
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TABLE 06- Dose wise distribution of inhalational 
steroids 
DOSAGE  (mcg) FREQUENCY(n) PERCENTAGE(%) 
80 1 3.6 
125 6 21.4 
250 7 25 
360 14 50 
Total 28 100.0 
 
 Out of 28 patients on inhalational steroids, 50% (n=14) were using 360 
mcg. 
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Chart 06- Dose wise distribution of inhalational 
steroids 
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Table 07- Frequency of dose wise distribution of the 
oral and inhalational steroids. 
DOSAGE 
(mg, mcg) 
FREQUENCY PERCENTAGE 
5,250 3 9.4 
5,360 7 21.9 
7.5,360 4 12.5 
10,80 1 3.1 
10,125 6 18.7 
10,250 6 18.7 
10,360 2 6.3 
15,250 3 9.4 
Total 32 100.0 
 
Table 08- Frequency of dose wise distribution of 
topical and subtenon steroids. 
DOSE (%) FREQUENCY PERCENTAGE 
0 211 91.7 
0.1% 13 5.7 
1% 1 0.4 
0.1%, 0.4cc 5 2.2 
Total 230 100 
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Table 09- Frequency of overall duration of use 
of steroids. 
 
DURATION 
(in months) 
FREQUENCY (n) 
PERCENTAGE 
(%) 
6-12 148   64.35 
13-24 44 19.13 
25-36 19 8.26 
37-48 12 5.22 
49-60 6 2.61 
61-72 1 0.43 
Total 230 100.0 
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Chart 07- Frequency of overall duration of use 
of steroids. 
 
 
 
Almost 64.35% of the patients (n=148) had taken steroids for 6 
to 12 months. Only one patient (0.4%) had taken steroids 
for >61 months duration.……………………………………….. 
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Table 10- Duration of use of various forms of steroids. 
           
 
DURATION 
(m) 
MINIMUM MAXIMUM MEAN STANDARD 
DEVIATION 
External 7 16 9.36 2.620 
Inhalational 7 48 29.68 12.114 
Oral 6 60 14.09 12.568 
Oral & 
Inhalational 
8 72 25.88 17.720 
Topical 6 16 9.93 3.174 
Topical &Sub-
tenon 
6 9 7.00 1.225 
Total 6 72 16.93 14.112 
 
Minimum duration of steroids used was 6 months and the 
maximum was 72 months. Mean duration of use of steroids was 
16.93 months with a standard deviation of 14.112.
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Chart 08- Duration of use of various forms of 
steroids 
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TABLE 11- Prevalence of lens opacities based on 
LOCS III 
 
CATARACT FREQUENCY (n) PERCENTAGE (%) 
P1 64 55.2 
P2 35 30.2 
P3 9 7.8 
P4 4 3.4 
P5 4 3.4 
Total 116 100.0 
 
 
Number of subjects who got any stage of lens opacities (PSCC) were 
116 (50.4%), of which P1 were 55.2% (n=64), P2 30.2% (n=35), least 
common were P4 and P5 with 3.4% (n=4). 
 
61 
 
Chart 09- Overall prevalence of lens opacities based 
on LOCS III 
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Table 12a - Prevalence of lens opacities in 
various forms of steroids. 
 
ROUTE OF 
ADMINISTRATION 
FREQUENCY (n) 
PERCENTAGE 
(%) 
External 1 0.82 
Inhalational 23 16.52 
Oral 57 53.72 
Oral & Inhalational 30 24.79 
Topical 5 4.13 
Topical & Sub-tenon 0 0 
Total 116 100.0 
 
In 116 patients who developed lens opacities, almost 54% (n=57) 
were oral steroid users, 25% (n=30) were oral and inhalational steroids 
users, 17% (n=23) were inhalational users, 4% (n=5) were topical users. 
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Chart 10-  Prevalence of lens opacities in various 
forms of steroids 
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TABLE- 12b-Frequency of prevalence of lens 
opacities in all forms of steroids 
LENS 
CHANG
ES 
 E I O O & I T T & 
ST 
Total 
n % n % n % n % n % n % n % 
C 13 92.9
% 
5 17.9
% 
80 58.4
% 
2 6.3
% 
9 64.
3% 
5 100
% 
114 49.6% 
P1 1 7.1% 13 46.4
% 
36 26.3
% 
11 34.4
% 
3 21.
4% 
0 0.0
% 
64 27.8% 
P2 0 0.0% 7 25.0
% 
13 9.5% 13 40.6
% 
2 14.
3% 
0 0.0
% 
35 15.2% 
P3 0 0.0% 2 7.1
% 
5 3.6% 2 6.3
% 
0 0.0
% 
0 0.0
% 
9 3.9% 
P4 0 0.0% 1 3.6
% 
2 1.5% 1 3.1
% 
0 0.0
% 
0 0.0
% 
4 1.7% 
P5 0 0.0% 0 0.0
% 
1 0.7% 3 9.4
% 
0 0.0
% 
0 0.0
% 
4 1.7% 
Total 14 100
% 
28 100
% 
137 100
% 
32 100
% 
14 100
% 
5 100
% 
230 100% 
 
 
93.8% (n=30) of oral and inhalational users developed lens opacities, 
followed by inhalational users with 82.2% (23), oral users with 41.6% 
(n=57), topical users 37.7% (n=14) and external users with 7.1% (n=1). 
With p value of 0.0001,  a statistically significant association was 
found between steroids used in any form with lens opacities formation. 
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Table 13-Prevalence of elevated intra-ocular pressure 
 
ELEVATED IOP 
(mm Hg) 
FREQUENCY(n) PERCENTAGE(%) 
22 to 25 73 80.0 
26 to 30 12 13.3 
31 to 35 4 4.4 
36 to 45 1 1.1 
Total 90 100 
 
In our study group 39.1% (n=90) got elevated IOP in one or both eyes.  
 CHART 11-Overall prevalence of elevated IOP 
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Table 14- Prevalence of elevation of IOP and C:D ratio with 
visual field defects 
 
ROUTE OF DRUG FREQUENCY(n) PERCENTAGE(%) 
E 1 6.7 
I 4 26.6 
O 9 60.0 
T 0 0.0 
O,T 1 6.7 
T,ST 0 0.0 
Total 15 100 
 
 
Chart 12- Prevalence of elevation of IOP and C:D ratio with 
visual field defects 
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Table 15a- Prevalence of elevated IOP in various form of steroids 
 
ROUTE OF 
ADMINISTRATION 
FREQUENCY (n) 
PERCENTAGE 
(%) 
External 2 2.15 
Inhalational 12 10.75 
Oral 44 51.61 
Oral & Inhalational 16 18.28 
Topical 11 11.83 
Topical & Sub-tenon 5 5.38 
Total 90 100.0 
 
Chart 13- Prevalence of elevated IOP in various form of steroids 
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Table 15b- Prevalence of elevated IOP in various routes of 
steroids 
RISE IN 
IOP 
 E I O O & I T T & 
ST 
Total 
n % n % n % n % n % n % n % 
< 21 12 85.7
% 
16 57.1
% 
93 67.9
% 
16 50.0
% 
3 21.4
% 
0 0.0
% 
140 60.9
% 
22-25 2 14.3
% 
6 21.4
% 
39 28.5
% 
15 46.9
% 
8 57.1
% 
3 60.0
% 
73 31.8
% 
26-30 0 0.0% 3 10.7
% 
3 2.2% 1 3.1
% 
3 21.4
% 
2 40.0
% 
12 5.2% 
31-35 0 0.0% 2 7.1
% 
2 1.4% 0 0.0
% 
0 0.0% 0 0.0
% 
4 1.7% 
36-45 0 0.0% 1 3.6
% 
0 0.0% 0 0.0
% 
0 0.0% 0 0.0
% 
1 0.4% 
Total 14 100
% 
28 100
% 
137 100
% 
32 100
% 
14 100
% 
5 100
% 
230 100
% 
 
 
100% (n=5) of topical and sub-tenon steroid users developed elevated 
IOP, followed by 78.5% (n=11) of topical, 50% (n=16) of oral & 
inhalational steroids, 43% (n=12) of inhalational, 32% (n=44) patients on 
oral steroids and 14.2% (n=2) of external users. With a p value of 0.0001 
statistically significant number of patients developed elevated IOP with 
steroids use in topical, topical with subtenon and inhalational routes..  
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Table 16- PREVALENCE OF CENTRAL 
SEROUS CHORIORETINOPATHY (CSCR) 
CSCR FREQUENCY(n) PERCENTAGE(%) 
Present 4 1.74 
Absent 216 98.26 
Total 230 100.0 
 
Number of patients developed CSCR were 4 (1.74%). 50% developed 
CSCR in right eye (n=2) and 50% in left eye (n=2).
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Table 17- CSCR PREVALENCE WITH 
VARIOUS ROUTE OF STEROIDS 
 
ROUTE OF 
ADMINISTRATION 
FREQUENCY (n) 
PERCENTAGE 
(%) 
External 0 0 
Inhalational 0 0 
Oral 3 75 
Oral & Inhalational 0 0 
Topical 0 0 
Topical & Sub-tenon 1 25 
Total 93 100.0 
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Chart 14- Prevalence of CSCR in various routes of 
steroids administration 
 
 
 
 
75% (n=3) developed CSCR were on oral steroids and 25% (n=1) were 
on topical and subtenon steroids.  
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Table 18- Frequency of prevalence of lens opacities 
and elevated IOP based on increase in dose of oral 
steroids 
Dosage (mg) 1-5 6-10 11-15 16-20 21-25 Total 
 
 
 
 
Lens 
opacit
ies 
No 
(n) 
43 30 6 0 1 80 
% 53.7% 37.5% 7.5% 0% 1.3% 100% 
Yes(n) 12 19 16 8 2 57 
% 21.1% 33.3% 28.1% 14.0% 3.5% 100% 
 
 
 
 
Elevat
ed 
IOP 
<21 mm 
Hg (n) 
34 42 13 3 1 93 
% 36.5% 45.2% 14% 3.2% 1.1% 100% 
>21 mm 
Hg (n) 
21 7 9 5 2 44 
% 47.7% 15.9% 20.5% 11.4% 4.5% 100% 
p value 0.0001 for dose and lens opacities (significant) 
p value 0.98 for dose and elevated IOP (not significant) 
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Chart 15- Frequency of prevalence of lens opacities and 
elevated IOP based on increase in dose of oral steroids 
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Table 19- Frequency of prevalence of lens opacities 
and elevated IOP based on increase in dose of 
inhalational steroids 
 
Dosage (mcg) 80 125 250 360 Total 
 
 
 
 
Lens 
opacit
ies 
No (n) 0 2 2 1 5 
% 0.0 40% 40% 20% 100% 
Yes (n) 1 4 4 13 22 
% 4.5% 18.2% 18.2% 59.1% 100% 
 
 
 
 
Elevat
ed 
IOP 
<21 mm 
Hg (n) 
0 2 3 11 16 
% 0.0% 12.5% 18.8% 68.7% 100% 
>21 mm 
Hg (n) 
1 4 4 3 12 
% 8.4% 33.3% 33.3% 25% 100% 
 
p value 0.0001 for dose and lens opacities (significant) 
p value 0.0001 for dose and elevated IOP (significant)
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Chart 16- Frequency of prevalence of lens opacities and 
elevated IOP based on increase in dose of inhalational 
steroids 
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Table 20- Frequency of prevalence of lens opacities 
and elevated IOP based on increase dose of both oral 
and inhalational steroids 
Dosage  
(mg, mcg) 
Lens opacities Elevated IOP 
No (n) % Yes 
(n) 
% <21 
(n) 
% >21
(n) 
% 
5,250 0 0.0% 3 10% 1 6.3% 2 12.5% 
5,360 0 0.0% 7 23.3% 1 6.3% 6 37.5% 
7.5,360 0 0.0% 4 13.3% 4 25% 0 0.0% 
10,80 0 00% 1 3.3% 0 0.0% 1 6.3% 
10,125 1 50% 5 16.7% 3 18.7
% 
3 18.7% 
10,250 1 50% 5 16.7% 3 18.7
% 
3 18.7% 
10,360 0 0.0% 2 6.7% 2 12.5
% 
0 0.0% 
15,250 0 0.0% 3 10% 2 12.5
% 
1 6.3% 
Total 2 100
% 
30 100% 16 100% 16 100% 
 
p value 0.0001 for dose and lens opacities (significant) 
p value 0.648 for dose and elevated IOP (not significant)
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Chart 17- Frequency of prevalence of lens opacities and elevated IOP 
based on increase dose of both oral and inhalational steroids 
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Table 21- Frequency of prevalence of lens opacities 
and elevated IOP based on duration 
DURATION (m) Lens opacities Elevated IOP 
No 
(n) 
% Yes 
(n) 
% <21 
(n) 
% >21
(n) 
% 
6-12 91 79.8% 56 48.3% 110 78.6
% 
37 41.1% 
13-24 14 12.3% 31 26.7% 20 14.3
% 
25 27.8% 
25-36 6 5.3% 13 11.2% 6 4.3% 13 14.4% 
37-48 1 0.9% 11 9.5% 2 1.4% 10 11.1% 
49-60 2 1.7% 4 3.4% 2 1.4% 4 4.5% 
61-72 0 0.0% 1 0.9% 0 0.0% 1 1.1% 
Total 114 100% 116 100% 140 100% 90 100% 
 
p value was 0.0001 for lens opacities and duration ( significant)               
p value was 0.0001 for elevated IOP and duration (significant)
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Chart 18- Frequency of prevalence of lens opacities and elevated IOP 
based on duration 
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Table 22- Prevalence of lens opacities and elevated 
IOP based on age 
 
Age (years) Lens opacities Elevated IOP 
No (n) % Yes (n) % <21 
(n) 
% >21
(n) 
% 
18 1 0.9% 0 0.0% 1 0.7% 0 0.0% 
21-30 34 29.9% 5 4.3% 31 22.1
% 
8 8.9% 
31-40 41 35.9% 39 33.6% 53 37.9
% 
27 30% 
41-50 38 33.3% 72 62.1% 55 39.3
% 
55 61.1% 
Total 114 100% 116 100% 140 100% 90 100% 
 
p value was 0.0001 for lens opacities and age ( significant) 
p value was 0.149 for elevated IOP and age (not significant) 
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Chart 19- Prevalence of lens opacities and elevated IOP based on age 
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Table 23- Prevalence of lens opacities and elevated 
IOP based on sex 
Sex Lens opacities Elevated IOP 
No (n) % Yes 
(n) 
% <21 
(n) 
% >21
(n) 
% 
Male 48 42.1% 53 45.7% 66 47.1% 35 38.9% 
Female 66 57.9% 63 54.3% 74 52.9% 55 61.1% 
Total 114 100% 116 100% 140 100% 90 100% 
 
p value was 0.660 for lens opacities and sex (not significant) 
p value was 0.668 for elevated IOP and sex (not significant) 
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Chart 20- Prevalence of lens opacities and elevated IOP based on sex 
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Table 24- Overall prevalence of ocular effects of long term 
steroids 
Ocular effect Frequency (n) Percentage (%) 
Lens opacities 116 50.4% 
Elevated IOP 90 39.1% 
Elevated IOP with 
disc & field changes 
15 6.5% 
CSCR 4 1.7% 
 
Chart 15- Overall prevalence of ocular manifestations of long term 
steroids 
50%
39%
6%
2%
0%
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percentage of patients with 
adverse effects
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DISCUSSION 
 
    Our study was conducted on 230 patients who were taking 
corticosteroids in various forms like oral, inhalational, external 
application and topical eye application for more than 6 months duration. 
The mean age of the patients in our study was 39.36 years with a 
standard deviation of 8.046 years. The youngest patient was 18 years and 
the oldest was 50 years. 
One patient was 18 years old (0.4%), 39 (17.0%) were in the age 
group of 21-30 years, 80 (34.8%) were in the age group of 31-40 years 
and 110 (47.8%) were in the age group of 41-50 years, in our study. 
Females were predominant in our study population (56.1%, n=129) 
and males comprised 43.9% (n=101). 
Patients in our study were on treatment with corticosteroids for 
various disease conditions in different routes of administration in 
rheumatology, thoracic medicine, dermatology and ophthalmology 
departments. 
Patients using external form of steroids were 14 (6.1%), inhalational 
steroids were 28 (12.2%), only oral were 137 (59.6%), both oral and 
inhalational steroids were 32 (13.9), topical steroids were 14 (6.1%) and 
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in both topical and sub-tenon injection steroids were 5 (2.2%). Our study 
group comprise a large subgroup of patients on oral steroids alone. 
Prednisolone was the most commonly used oral drug in our study group. 
In which patient taking < 5mg were 55, 6-10 mg were 49, 11-15 mg were 
22, 16-25 mg were 11. Mean dosage used in our study group is 8.97 mg 
with a standard deviation of  
Mean duration for which various forms of steroids used were 16.93 
months with a standard deviation of 14.112. 
The prevalence of lens opacities graded by LOCS III among the total 
study population 230 was 50.4% ( n=116). Among them almost 89.7% 
(n=104) had only PSCC type of lens opacities. 12 patients (10.3%) had 
both PSCC and non-PSCC type of lens opacities. 
Prevalence of lens opacities among various route of steroid 
administration is given in the table 12a, comprise the external users 0.9% 
(n=1), inhalational users 19.8% (n=23), only oral users 49.1% (n=57), 
both oral and inhalational users 25.9% (n=30), and topical users 4.3% 
(n=5) had lens opacities. 
93.8% (n=30) of combined oral and inhalational users developed 
lens opacities, followed by inhalational users with 82.2% (23), oral users 
with 41.6% (n=57), topical users 37.7% (n=14) and external users with 
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7.1% (n=1). A statistically significant association was found between 
steroids used in any form with lens opacities formation with a p value of 
<0.001. 
Based upon the dosage of various forms of steroids, oral form, 
inhalational and oral and inhalational form showed significant association 
between development of lens opacities with increase in the dose with a p 
value < 0.001. 
Based upon the duration, a strong association was found between the 
development of lens opacities with increase in the duration irrespective of 
the route of administration of steroids with a p value <0.001. 
Prevalence of elevated IOP (>22 mm Hg) in our study group was 
39.1% (n=90), of which patients with IOP ranging from 22 to 25 mm Hg 
were 80% (n=73), 26 to 30 mm Hg were 13.3% (n=12), 31 to 35 mm Hg 
were 4.4% (n=4) and 36 to 45 mm Hg were 1.1% (n=1).  
Mean IOP was 19.96 mm Hg with a standard deviation of 4.272. 
The prevalence of elevated IOP with increase in C:D ratio and visual field 
defects were 15 (16.7%) with a p value of 0.001 with statistically higher 
significance. 
Out of the 90 patients with elevated IOP, 2.2% (n=2) were on 
external steroids, 13.3% (n=12) were inhalational, 48.9% (n=44) were 
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oral, 17.8% (n=16) were both oral and inhalational, 12.2% (n=11) were 
topical and 5.6% (n=5) were topical and subtenon injection users. 
100% (n=5) of topical and sub-tenon steroid users developed 
elevated IOP, followed by 78.5% (n=11) of topical, 50% (n=16) of oral & 
inhalational steroids, 43% (n=12) of inhalational, 32% (n=44) patients on 
oral steroids and 14.2% (n=2) of external users. With a p value of 0.001 
statistically significant number of patients developed elevated IOP with 
steroids use in any form.  
Based upon the dosage of various forms of steroids, topical form and 
inhalational form showed significant association between elevation of 
IOP with increase in the dose with p value <0.001. No significant 
association seen between oral and combined oral with inhalational 
steroids dose with the prevalence of elevated IOP with a p value 0.9 and 
0.6 respectively. 
Based upon the duration, a strong association was found between the 
elevation of IOP with increase in the duration irrespective of the route of 
administration of steroids with a p value <0.001. 
Most of them were treated with topical anti-glaucoma medications 
with single or double drug regimen with tapering the dose of steroid to 
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minimal therapeutic dose or by stopping them in some patients with 
uncontrolled IOP. One patient needed trabeculectomy to control the IOP. 
In our study group, 4 patients developed CSCR (1.7%). Of which 3 
patients used oral steroids and 1 patient had both topical and sub-tenon 
steroids. The mean duration of manifestation of CSCR was 32.4 months 
in patients on oral steroids and 28 months in patients on topical steroids. 
50% (n=2) developed CSCR in right eye and 50% (n=2) in left eye. 
Overall 50.4% (n=116) of the study group developed lens opacities, 
39.1% (n=90) developed elevated IOP, 6.5% (n=15) developed elevated 
IOP with disc and visual field defects and 1.7% (n=4) developed CSCR.  
Drawback of the study were 1. all patients <50 years of age were 
presumed to have clear lens. Hence, any grade of lens opacities was taken 
as significant and assumed to be due to steroid therapy. 2. 21 mm Hg was 
the maximum physiological IOP in normal population. Hence, IOP more 
than 21 mm Hg was taken as elevated IOP in our study. Some patients 
may have had POAG or some may have had high baseline IOP. All the 
above conditions could not be ruled out since this was a cross-sectional 
study. Hence it could not be stated that elevated IOP was really due to 
steroids therapy in each and every case. Hence as further scope in similar 
future studies, it is recommended to record baseline IOP before starting 
steroid therapy to improve the value of the study.
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SUMMARY 
Our study titled “AN ANALYTICAL STUDY OF THE 
OCULAR EFFECTS IN PATIENTS ON LONG TERM 
CORTICOSTEROIDS” was a hospital based cross-sectional study. 
The aim of the study was to analyse the ocular effects of long term 
use of corticosteroids by various routes of administration for various 
disorders treated in a tertiary care hospital. 
The objective was to study the  prevalence of ocular manifestations 
of chronic use of corticosteroids in various diseases and to emphasise the 
importance of regular ocular examination for the patients on long term     
steroid therapy in any form. 
Almost 50% of our study group developed lens opacites, 39% 
developed elevated IOP, of which 15 patients developed elevated IOP 
with significant disc and visual field changes. 1.7% of our study group 
developed CSCR. 
The prevalence of lens opacities showed significant association 
with all routes of steroid intake, duration of the therapy and dose of the 
drug. 
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The prevalence of elevated IOP showed significant association 
with topical, topical with subtenon and inhalational drugs and not 
significant with oral and external steroids. 
Age of the study group who showed significant association with 
lens opacities were 41-50 years (74 patients). But there was no 
significant correlation between the elevated IOP and CSCR with the 
age. Sex showed no significant association for the development of lens 
opacities, elevated IOP or CSCR. 
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CONCLUSION  
Corticosteroids are most widely used anti-inflammatory drug in 
various specialities. Steroids are used in different doses, frequency, 
duration and different routes. Though most of their adverse effects are 
well documented, the pathogenesis behind them is very poorly 
understood so far. There are many studies documenting the benefits, 
adverse effects and safety measures to be taken while prescribing 
steroids, but still we are lacking in pre-treatment documentation of 
various parameters especially ophthalmological examination, screening 
for adverse effects and timely management of the adverse effects. 
The main objective of our study is to document the prevalence 
of common ocular manifestations like lens opacities, steroids-induced 
elevated IOP, and CSCR in the patients taking long-term steroids (> 
6months) and to sensitize the treating physicians who are using steroids 
on long term to use them judicially and refer the patients for pre-
treatment evaluation and intermittent re-evaluation since the prevalence 
of adverse effects are found to be in significant numbers in our study.  
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PROFORMA 
NAME         :  
AGE           : 
SEX           :  
OP / PIN NO  : 
History : 
1. Presenting Complaint      - 
2. Associated symptoms      - 
3. Blurring of vision         - 
4. Glare                       - 
5. Uniocular polyopia         - 
6. Coloured haloes            - 
7. Black spots in front of eyes - 
8. Day blindness              - 
9. Headache and eye ache     - 
10. Scotoma                  - 
11. Metamorphopsia/micropsia - 
Past history                           : DM/ SHT/ Ocular traumas, Similar  
complaints in the past 
Medical history: systemic disease :  
Form and dose of steroid use      : 
Duration of use                    : 
Ocular Examination     : 
RE   LE 
Uncorrected Visual acuity (UCVA) :       
Refraction                          : SPH 
                                      CYL 
                                      AXIS 
Best corrected visual acuity(BCVA): 
Near vision                         : 
Intra-ocular pressure                : 
(with Goldmann Applanation Tonometer) 
 
Slit lamp examination: 
 RE        LE 
Lids                  : 
Conjunctiva          : 
Cornea               : 
Anterior chamber     : 
Iris                   : 
Pupil                 : 
Lens                 :       
Extra ocular movements : 
Fundus examination : 
Direct Ophthalmoscopy,  +90D and Indirect Ophthalmoscopy. 
RIGHT EYE                      LEFT EYE 
 
                                    
 
 
Visual fields          : 
Colour vision         : 
Blood pressure        : 
Biochemical investigations: 
Random blood sugar        - 
FBS/PPBS  (if required)    - 
OCT: (if required) 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
Here by I volunteer and consent to participate  in  this  study  
"ANALYTICAL STUDY OF THE OCULAR EFFECTS IN 
PATIENTS ON LONG TERM CORTICOSTEROIDS”. I was fully 
explained about the nature of this study by the doctor; knowing which I 
Mr / Ms……………….. fully consent to volunteer in this study. 
 
 
 
 
 
 
 
 
 
Signature of the volunteer  
Date: 
Place:                                          Signature of the witness 
 
 
 
 
 
 
 
CONSENT FORM 
 
I Dr. SHALINI. G is carrying out a study on the topic, "AN 
ANALYTICAL STUDY OF THE OCULAR EFFECTS IN PATIENTS 
ON LONG TERM CORTICOSTEROIDS” 
My research project guide is Dr.S.PADMANABAN M.S.,D.O. 
 
My research project is being carried out in the Department of 
Ophthalmology, Coimbatore Medical  College  Hospital, Coimbatore. 
RESEARCH BEING DONE: 
AN ANALYTICAL STUDY OF THE OCULAR EFFECTS IN 
PATIENTS ON LONG TERM CORTICOSTEROIDS. 
 
PURPOSE OF RESEARCH 
 
To study the prevalence of various ocular effects of long term use of 
corticosteroids in various diseases. 
To emphasis the importance of regular ocular examination for the patients 
on long term steroid therapy. 
 
PROCEDURES INVOLVED: 
 
Detailed history including the past medical history and treatment history, 
form, frequency and duration of usage of corticosteroids is recorded. Blood 
pressure and blood sugar are recorded. 
A comprehensive ophthalmological examination was done including 
visual acuity, intra-ocular pressure measurement, colour vision, visual 
fields, slit lamp biomicroscopy and ophthalmoscopic examination. 
You, Shri./ Smt./ Kum.  , 
aged ………….  years,  S/o  /  D/o / W/o  , 
residing at……………………………………………………………. are 
requested to be a participant in the research study titled ‘AN 
ANALYTICAL STUDY OF THE OCULAR EFFECTS IN 
PATIENTS ON LONG TERM CORTICOSTEROIDS’ in Government 
Medical College Hospital, Coimbatore. You satisfy eligibility criteria as 
per the inclusion criteria. You can ask any questions or seek any 
clarifications on the study that you may have before agreeing to 
participate. 
DECLINE FROM PARTICIPATION 
You are hereby made aware that participation in this study is purely  
voluntary  and  honorary  and  that  you  have  the  option  and  
the right to decline from participation in the study. 
PRIVACY AND CONFIDENTIALITY 
 
You are  hereby  assured  about  your  privacy.  Privacy of  subject 
will be respected and any information about  you  or provided by you 
during the study  will  be  kept  strictly  confidential. 
AUTHORIZATION TO PUBLISH RESULTS 
 
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified; neither 
will your privacy be breached. 
STATEMENT OF CONSENT 
 
I,  , do  hereby  volunteer  
and   consent to participate in  this  study  being  conducted  by  
Dr.Shalini. G I have read and understood the consent form / or it has been 
read and explained  to me  in  my  own  language. The study has been 
fully explained to me, and whenever I ask questions at any time. 
 
 
 
Signature / Left  Thumb  Impression  of the Volunteer 
Date:                             
Signature and Name of witness   
Date: 
åŠ¹î™ ð®õ‹ 
 
ªðò˜   :   
õò¶   :    
ð£Lù‹   : 
ºèõK   : 
 
«è£¬õ Üó² ñ¼ˆ¶õ‚ è™ÖK ñ¼ˆ¶õñ¬ùJ™ ñ¼.F.#hypdp î¬ô¬ñJ™ 
ï¬ìªðÁ‹ Þ‰î ÝŒM™ âù¶ º¿àì™ ñŸÁ‹ btFehs] fhh]l]onfh!]ouha]]l]!]  
cgnahfpg]gjhy] fz]zpy] Vw]gLk] gpd]tpist[fspd] Ma]t[ ªêŒ¶ ªè£œ÷ 
º¿ ñù¶ì¡ ê‹ñF‚A«ø¡. â¡¬ùŠ ðŸPò Mõóƒè¬÷ ð£¶è£Š¹ì¡ Þ‰î ÝŒM™ 
ªõOJì Ý†«êð¬í Þ™¬ô â¡Á ªîKMˆ¶‚ ªè£œA«ø¡. ï£¡ â‰î «ïóˆF½‹ ÝŒM™ 
Þ¼‰¶ Mô‚A‚ ªè£œÀ‹ àK¬ñ à‡´ â¡Á ÜP«õ¡. 
 
 
 
 
Þì‹        ¬èªò£Šð‹/¬è«ó¬è 
 
«îF 
                    
 
 
 
 
 
KEY TO MASTER CHART 
 
M -  Male      
F  - Female                  
mg   -  milligram           
mcg   -  microgram         
BA    -  Bronchial Asthma 
RA    -  Rheumatoid Arthritis 
SLE    -  Systemic Lupus Erythematosis 
ILD    -  Interstitial Lung Disease 
O     -  Oral                
COPD  -  Chronic Obstructive Pulmonary Disease 
I      -  Inhalational         
ENL   -  Erythema Nodosu Leprosum 
E     -  External            
UCTD -  Undifferentiated connective tissue disorder 
T     -  Topical                  
SS    -  Systemic sclerosis 
ST    -  Subtenon                
TB    -  Tuberculosis 
RE    -  Right eye                
CAU   -  Chronic Anterior Uveitis 
LE    -  Left Eye                 
IU     -  Intermediate Uveitis 
m    -  Months                   
PU    -  Posterior Uveitis 
BP    -  Blood Pressure            
VKH   -  Vogt-Koyanaki-Harada 
RBS   -  Random blood sugar       
PV    -  Pempigus vulgaris 
mg/dl   -  milligram/deciliter       
PN    -  Polyarthritis nodosa 
C      -  Clear                   
LR    -  Lepra Reaction 
N     -  Normal                  
SD    -  Scleroderma 
C:D    -  Cup, disc ratio            
VIT   -  Vitiligo 
PU    -  Posterior Uveitis          
PR    -  Polymayalgia Rheumatica 
DM   -  Dermatomyositis         
NS   -  Nephrotic Syndrome 
CSCR  -  Central Serous Chorioretinopathy 
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